GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00464564 | Cervix | CC | icosanoid biosynthetic process | 15/2311 | 56/18723 | 2.60e-03 | 1.80e-02 | 15 |
GO:0070206 | Cervix | CC | protein trimerization | 7/2311 | 17/18723 | 2.72e-03 | 1.85e-02 | 7 |
GO:20003779 | Cervix | CC | regulation of reactive oxygen species metabolic process | 32/2311 | 157/18723 | 2.78e-03 | 1.87e-02 | 32 |
GO:19013423 | Cervix | CC | regulation of vasculature development | 60/2311 | 348/18723 | 4.48e-03 | 2.72e-02 | 60 |
GO:00457653 | Cervix | CC | regulation of angiogenesis | 59/2311 | 342/18723 | 4.73e-03 | 2.83e-02 | 59 |
GO:00302781 | Cervix | CC | regulation of ossification | 24/2311 | 115/18723 | 6.51e-03 | 3.61e-02 | 24 |
GO:0030501 | Cervix | CC | positive regulation of bone mineralization | 11/2311 | 40/18723 | 7.54e-03 | 4.02e-02 | 11 |
GO:00069597 | Cervix | CC | humoral immune response | 54/2311 | 317/18723 | 8.57e-03 | 4.42e-02 | 54 |
GO:0031214 | Cervix | CC | biomineral tissue development | 32/2311 | 169/18723 | 8.73e-03 | 4.48e-02 | 32 |
GO:00158337 | Cervix | CC | peptide transport | 46/2311 | 264/18723 | 9.69e-03 | 4.78e-02 | 46 |
GO:19034095 | Cervix | CC | reactive oxygen species biosynthetic process | 15/2311 | 64/18723 | 9.89e-03 | 4.85e-02 | 15 |
GO:0030282 | Cervix | CC | bone mineralization | 24/2311 | 119/18723 | 1.00e-02 | 4.89e-02 | 24 |
GO:0110148 | Cervix | CC | biomineralization | 32/2311 | 171/18723 | 1.04e-02 | 4.97e-02 | 32 |
GO:004578515 | Cervix | HSIL_HPV | positive regulation of cell adhesion | 48/737 | 437/18723 | 1.37e-10 | 4.72e-08 | 48 |
GO:000715913 | Cervix | HSIL_HPV | leukocyte cell-cell adhesion | 43/737 | 371/18723 | 2.38e-10 | 7.02e-08 | 43 |
GO:000697915 | Cervix | HSIL_HPV | response to oxidative stress | 48/737 | 446/18723 | 2.76e-10 | 7.02e-08 | 48 |
GO:000695912 | Cervix | HSIL_HPV | humoral immune response | 39/737 | 317/18723 | 2.88e-10 | 7.02e-08 | 39 |
GO:002240713 | Cervix | HSIL_HPV | regulation of cell-cell adhesion | 47/737 | 448/18723 | 9.91e-10 | 2.08e-07 | 47 |
GO:190303712 | Cervix | HSIL_HPV | regulation of leukocyte cell-cell adhesion | 38/737 | 336/18723 | 5.31e-09 | 7.61e-07 | 38 |
GO:190303912 | Cervix | HSIL_HPV | positive regulation of leukocyte cell-cell adhesion | 31/737 | 239/18723 | 5.53e-09 | 7.61e-07 | 31 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ALOX5 | SNV | Missense_Mutation | | c.1112N>A | p.Arg371Gln | p.R371Q | P09917 | protein_coding | tolerated(0.21) | benign(0.03) | TCGA-GM-A3NW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
ALOX5 | insertion | In_Frame_Ins | novel | c.230_231insAAACTG | p.Asn78_Asp79insTrpAsn | p.N78_D79insWN | P09917 | protein_coding | | | TCGA-A2-A0EM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
ALOX5 | insertion | Nonsense_Mutation | novel | c.211_212insCTTCAACTTCCCAACCTTGATGAAAAGAGTGTT | p.Glu71delinsAlaSerThrSerGlnProTerTerLysGluCysTer | p.E71delinsASTSQP**KEC* | P09917 | protein_coding | | | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
ALOX5 | insertion | Nonsense_Mutation | novel | c.323_324insGTGA | p.Glu109Ter | p.E109* | P09917 | protein_coding | | | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |
ALOX5 | insertion | Frame_Shift_Ins | novel | c.324_325insAAATTCTTAACACCTCCAGAACAAAGGCTCAG | p.Glu109LysfsTer15 | p.E109Kfs*15 | P09917 | protein_coding | | | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |
ALOX5 | SNV | Missense_Mutation | rs778612367 | c.431G>A | p.Arg144Gln | p.R144Q | P09917 | protein_coding | deleterious(0.03) | possibly_damaging(0.764) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ALOX5 | SNV | Missense_Mutation | novel | c.106C>T | p.His36Tyr | p.H36Y | P09917 | protein_coding | tolerated(0.41) | possibly_damaging(0.792) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ALOX5 | SNV | Missense_Mutation | | c.883N>A | p.Ala295Thr | p.A295T | P09917 | protein_coding | tolerated(0.42) | benign(0.187) | TCGA-EA-A5ZF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
ALOX5 | SNV | Missense_Mutation | | c.685N>A | p.Glu229Lys | p.E229K | P09917 | protein_coding | deleterious(0.01) | benign(0.044) | TCGA-EK-A2H0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ALOX5 | SNV | Missense_Mutation | novel | c.517N>A | p.Glu173Lys | p.E173K | P09917 | protein_coding | tolerated(0.17) | possibly_damaging(0.771) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |